T cell antigen receptor vaccines for active therapy of T cell malignancies

Ann N Y Acad Sci. 2001 Sep;941:97-105. doi: 10.1111/j.1749-6632.2001.tb03714.x.

Abstract

T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / therapeutic use
  • Base Sequence
  • Cancer Vaccines*
  • Genetic Vectors
  • Humans
  • Immunoglobulin Idiotypes / therapeutic use
  • Lymphoproliferative Disorders / therapy
  • Mice
  • Mycosis Fungoides / therapy*
  • Polymerase Chain Reaction
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / therapeutic use*
  • Skin Neoplasms / therapy*
  • Survival Rate
  • Vaccines, DNA

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • Immunoglobulin Idiotypes
  • Receptors, Antigen, T-Cell
  • Vaccines, DNA